ARTICLE | Clinical News
Sativex: Phase III started
December 6, 2010 8:00 AM UTC
GW and Otsuka began the first of 2 placebo-controlled, international Phase III trials to evaluate 3-10 daily sprays of Sativex for 5 weeks in 370 patients who experience inadequate analgesia during op...